Cancer Drug Target Validation
Led by a group of expert scientists, Frontage has expertise in cancer drug discovery and development.
- Cancer molecular target genetic screening
- Cancer cell biology and pharmacology
- Patient-derived orthotopic sub-renal capsule xenograft mouse model development
- Unique In vivo DM/PK/ADME characterization of “drug-like” properties in patient-derived xenograft
- Integrated LC/MS/MS and biological assays supporting discovery and IND and NDA-enabling development studies
ANTI-CANCER DRUG DISCOVERY & DEVELOPMENT
In Vitro Cell Line Anticancer Activity Screening
- Drug efficacy screening assays using commercial ATCC human cancer cell lines with known genetic characteristization
In Vivo Cell Line Xenograft Drug Efficacy Study
- Utilize commercial cell lines or cell line provided by sponsor to generate subcutaneous, subrenal capsule or other orthotopic xenograft models for drug efficacy studies
- Generate pharmacokinetic data from the same experiment based on serial blood sampling for LC/MS/MS assay to provide PK/PD correlation
In Vivo Patient-Derived Orthotopic Xenograft Translational Efficacy Study
- Translational efficacy study based on patient-derived tumors established in NOD-SCID mice
- Highly recognized expertise and excellent track record on development of patient-derived tumor xenografts of various cancers including cancers the prostate, ovary, lung, pancreas, skin, uterus, colon, kidney, bone, breast sarcoma and lymphoma
- Generate pharmacokinetic data from the same experiment based on serial blood sampling for LC/MS/MS assay to provide PK/PD correlation
Uniquely Integrated In Vivo Anticancer Drug Efficacy Study Design
- Inhibition of tumor growth and metastases efficacy endpoints
- Pharmacokinetics and ADME data for PK/PD correlation
- Survival endpoint and adverse events monitoring
- Histopathological evaluation
- Molecular targets and biomarker evaluation